PL2049109T3 - Skojarzone zastosowanie kwasu (+)-1,4-dihydro-7-[(3s,4s)-3-metoksy-4-(metyloamino)-1-pirolidynylo]-4-okso-1-(2-tiazolilo)-1,8-naftyrydyno-3-karboksylowego i cytarabiny (Ara-C) do leczenia białaczki - Google Patents
Skojarzone zastosowanie kwasu (+)-1,4-dihydro-7-[(3s,4s)-3-metoksy-4-(metyloamino)-1-pirolidynylo]-4-okso-1-(2-tiazolilo)-1,8-naftyrydyno-3-karboksylowego i cytarabiny (Ara-C) do leczenia białaczkiInfo
- Publication number
- PL2049109T3 PL2049109T3 PL07811049T PL07811049T PL2049109T3 PL 2049109 T3 PL2049109 T3 PL 2049109T3 PL 07811049 T PL07811049 T PL 07811049T PL 07811049 T PL07811049 T PL 07811049T PL 2049109 T3 PL2049109 T3 PL 2049109T3
- Authority
- PL
- Poland
- Prior art keywords
- naphthyridine
- ara
- cytarabine
- pyrrolidinyl
- methylamino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83523906P | 2006-08-02 | 2006-08-02 | |
US87376006P | 2006-12-08 | 2006-12-08 | |
PCT/US2007/017344 WO2008016702A2 (en) | 2006-08-02 | 2007-08-02 | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic |
EP07811049.1A EP2049109B1 (en) | 2006-08-02 | 2007-08-02 | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2049109T3 true PL2049109T3 (pl) | 2016-05-31 |
Family
ID=38859094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07811049T PL2049109T3 (pl) | 2006-08-02 | 2007-08-02 | Skojarzone zastosowanie kwasu (+)-1,4-dihydro-7-[(3s,4s)-3-metoksy-4-(metyloamino)-1-pirolidynylo]-4-okso-1-(2-tiazolilo)-1,8-naftyrydyno-3-karboksylowego i cytarabiny (Ara-C) do leczenia białaczki |
Country Status (12)
Country | Link |
---|---|
US (3) | US20080063642A1 (pl) |
EP (2) | EP3025712A1 (pl) |
JP (4) | JP2009545601A (pl) |
CA (1) | CA2659861A1 (pl) |
CY (1) | CY1119309T1 (pl) |
DK (1) | DK2049109T3 (pl) |
ES (1) | ES2556677T3 (pl) |
HU (1) | HUE026693T2 (pl) |
MX (1) | MX344865B (pl) |
PL (1) | PL2049109T3 (pl) |
SI (1) | SI2049109T1 (pl) |
WO (1) | WO2008016702A2 (pl) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1729770T3 (da) * | 2004-03-15 | 2010-04-12 | Sunesis Pharmaceuticals Inc | SNS-595 og fremgangsmåder til anvendelse deraf |
US8580814B2 (en) | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
US8124773B2 (en) | 2006-06-12 | 2012-02-28 | Sunesis Pharmaceuticals, Inc. | 1,8-naphthyridine compounds for the treatment of cancer |
WO2008016678A2 (en) * | 2006-08-01 | 2008-02-07 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
JP6029808B2 (ja) | 2007-10-22 | 2016-11-24 | サネシス ファーマシューティカルズ, インコーポレイテッド | 併用療法における(+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の使用方法 |
EP2249831A2 (en) * | 2007-12-10 | 2010-11-17 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
EP3284745A1 (en) | 2008-12-31 | 2018-02-21 | Sunesis Pharmaceuticals, Inc. | Composition of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
UA110465C2 (en) | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
US8470817B2 (en) * | 2009-10-26 | 2013-06-25 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
CN109224064A (zh) * | 2009-12-04 | 2019-01-18 | 昂科免疫有限公司 | 低氧诱导因子抑制剂的用途 |
RU2550663C2 (ru) * | 2013-02-13 | 2015-05-10 | Владимир Владимирович Савостьянов | Способ гормонально-лучевой подготовки больных хроническим лимфолейкозом к последующей химиотерапии |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
AU2015315396B2 (en) | 2014-09-09 | 2020-10-08 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
AU2015358615B2 (en) * | 2014-12-04 | 2021-08-05 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute myeloid leukemia |
JP6851989B2 (ja) | 2015-05-18 | 2021-03-31 | シン−ナット プロダクツ エンタープライズ エルエルシー | 医薬用共結晶及びその用途 |
EP3297729A4 (en) | 2015-05-20 | 2019-04-10 | Janssen Biotech, Inc. | ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT CHAINS AMYLOIDOSIS AND OTHER CD38-POSITIVE HEMATOLOGICAL TUMORS |
EP3297636B1 (en) | 2015-06-19 | 2021-02-17 | Syn-Nat Products Enterprise LLC | Pharmaceutical composition of carboplatin based co-crystals and use thereof |
BR112017027277A2 (pt) * | 2015-06-19 | 2018-09-04 | Syn Nat Products Entpr Llc | ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula? |
US10668149B2 (en) | 2015-06-22 | 2020-06-02 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
JP6929234B2 (ja) | 2015-06-25 | 2021-09-01 | シン−ナット プロダクツ エンタープライズ エルエルシー | 医薬共結晶組成物及びその用途 |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
RS63210B1 (sr) | 2015-11-03 | 2022-06-30 | Janssen Biotech Inc | Potkožne formulacije anti-cd38 antitela i njihova upotreba |
AU2018359527A1 (en) | 2017-10-31 | 2020-05-07 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5382525A (en) * | 1992-11-27 | 1995-01-17 | American Air Liquide | Method of effecting increased performance of diagnostic enzyme reaction systems using noble gases |
US5360352A (en) * | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
DK0787726T3 (da) * | 1994-06-14 | 2002-02-11 | Dainippon Pharmaceutical Co | Ny forbindelse, fremgangsmåde til fremstilling deraf og antitumor-middel |
JPH10173986A (ja) | 1996-12-16 | 1998-06-26 | Sony Corp | 移動体撮影装置 |
EP1003856A1 (en) * | 1997-06-05 | 2000-05-31 | Board of Regents, The University of Texas System | Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
US6171857B1 (en) * | 1997-10-17 | 2001-01-09 | Brown University Research Foundatiion | Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity |
US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
US6670144B1 (en) * | 1999-02-26 | 2003-12-30 | Cyclacel, Ltd. | Compositions and methods for monitoring the phosphorylation of natural binding partners |
AU760466B2 (en) * | 1999-02-26 | 2003-05-15 | Johns Hopkins University, The | A novel inhibitor of programmed cell death |
US7163801B2 (en) * | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
AU2001296558A1 (en) * | 2000-10-03 | 2002-04-15 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
DK1729770T3 (da) | 2004-03-15 | 2010-04-12 | Sunesis Pharmaceuticals Inc | SNS-595 og fremgangsmåder til anvendelse deraf |
US20050222267A1 (en) * | 2004-04-01 | 2005-10-06 | Truong Van H | Solution based methacholine formulations |
EP1931339B1 (en) | 2005-09-02 | 2018-05-16 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
-
2007
- 2007-08-02 CA CA002659861A patent/CA2659861A1/en not_active Abandoned
- 2007-08-02 JP JP2009522883A patent/JP2009545601A/ja active Pending
- 2007-08-02 PL PL07811049T patent/PL2049109T3/pl unknown
- 2007-08-02 SI SI200731723T patent/SI2049109T1/sl unknown
- 2007-08-02 ES ES07811049.1T patent/ES2556677T3/es active Active
- 2007-08-02 MX MX2009001130A patent/MX344865B/es active IP Right Grant
- 2007-08-02 DK DK07811049.1T patent/DK2049109T3/en active
- 2007-08-02 EP EP15189348.4A patent/EP3025712A1/en not_active Withdrawn
- 2007-08-02 EP EP07811049.1A patent/EP2049109B1/en not_active Revoked
- 2007-08-02 HU HUE07811049A patent/HUE026693T2/hu unknown
- 2007-08-02 US US11/890,196 patent/US20080063642A1/en not_active Abandoned
- 2007-08-02 WO PCT/US2007/017344 patent/WO2008016702A2/en active Application Filing
-
2013
- 2013-09-25 JP JP2013198807A patent/JP2014040437A/ja active Pending
-
2014
- 2014-08-15 US US14/461,271 patent/US20150190380A1/en not_active Abandoned
-
2015
- 2015-11-09 JP JP2015219880A patent/JP6189911B2/ja not_active Expired - Fee Related
- 2015-12-15 CY CY20151101147T patent/CY1119309T1/el unknown
-
2016
- 2016-06-03 US US15/173,506 patent/US20170119745A1/en not_active Abandoned
-
2017
- 2017-08-03 JP JP2017150849A patent/JP2017226683A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
JP2017226683A (ja) | 2017-12-28 |
EP3025712A1 (en) | 2016-06-01 |
ES2556677T3 (es) | 2016-01-19 |
WO2008016702A3 (en) | 2008-03-20 |
WO2008016702A2 (en) | 2008-02-07 |
CA2659861A1 (en) | 2008-02-07 |
EP2049109A2 (en) | 2009-04-22 |
JP6189911B2 (ja) | 2017-08-30 |
HUE026693T2 (hu) | 2016-07-28 |
CY1119309T1 (el) | 2018-02-14 |
MX344865B (es) | 2016-12-19 |
EP2049109B1 (en) | 2015-11-18 |
US20150190380A1 (en) | 2015-07-09 |
JP2014040437A (ja) | 2014-03-06 |
US20170119745A1 (en) | 2017-05-04 |
SI2049109T1 (sl) | 2016-04-29 |
DK2049109T3 (en) | 2016-01-11 |
MX2009001130A (es) | 2009-05-13 |
JP2016053070A (ja) | 2016-04-14 |
JP2009545601A (ja) | 2009-12-24 |
US20080063642A1 (en) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2049109T3 (pl) | Skojarzone zastosowanie kwasu (+)-1,4-dihydro-7-[(3s,4s)-3-metoksy-4-(metyloamino)-1-pirolidynylo]-4-okso-1-(2-tiazolilo)-1,8-naftyrydyno-3-karboksylowego i cytarabiny (Ara-C) do leczenia białaczki | |
WO2009075841A3 (en) | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders | |
AP2007004095A0 (en) | Cxcr4 antagonists for the treatment of hiv infection | |
IL225198A (en) | Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes | |
WO2008127364A3 (en) | Antiviral compounds and use thereof | |
IL185277A0 (en) | Pharmaceutical compositions containing roflumilast for the treatment of diabetes | |
WO2007146425A3 (en) | Compounds and methods for treatment of chemotherapy-induced anemia | |
HK1108686A1 (en) | 3-azetidinecarboxylic acid derivatives for use as immunosuppressants | |
EP1713773A4 (en) | N-BENZYL-3,4-DIHYDROXYPYRIDINE-2-CARBOXYLIC AMID AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXYLIC AMIDE COMPOUNDS SUITABLE AS INHIBITORS OF THE HIV INTEGRASE | |
IL187904A (en) | Use of quinoline derivatives for the preparation of bacterial preparations for the treatment of bacteria caused by bacteria | |
EP2048153A4 (en) | SUBSTITUTED SPIROCETAL DERIVATIVE AND USE THEREOF AS A MEDICAMENT IN THE TREATMENT OF DIABETES | |
HK1107343A1 (en) | Bicyclic heterocycles as hiv integrase inhibitors | |
EP1868628A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING POXVIRUS INFECTIONS | |
HK1115752A1 (en) | Benzazole derivatives, compositions, and methods of use as | |
IL178141A0 (en) | Combinations for treating hiv infection | |
EP1870015A4 (en) | ENDOSCOPE FIXATION, ENDOSCOPE TREATMENT INSTRUMENT AND ENDOSCOPIC SYSTEM | |
EP1749008A4 (en) | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | |
EP1720863A4 (en) | HETEROARYLAMINOPYRAZOLE DERIVATIVES FOR TREATING DIABETES | |
EP1874301A4 (en) | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SAME, AND METHODS OF TREATMENT | |
IL187235A0 (en) | 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament | |
WO2010078294A8 (en) | Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | |
IL186676A0 (en) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility | |
CL2007003519A1 (es) | Compuestos derivados de quinolina sustituida; proceso de preparacion; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una infeccion bacteriana. | |
PL1879581T3 (pl) | Pochodne 4-fenylo-5-okso-1,4,5,6,7,8-heksahydrochinoliny jako leki do leczenia niepłodności | |
EP1750698A4 (en) | 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES |